The titers of antinuclear antibodies are associated with the degree of inflammation and organ damage in Primary Sjögren's Syndrome.
Anti-SSA antibodies
Anti-SSB antibodies
Antinuclear antibodies
Multi-organ damage
Primary Sjogren’s syndrome
Journal
Clinical and experimental medicine
ISSN: 1591-9528
Titre abrégé: Clin Exp Med
Pays: Italy
ID NLM: 100973405
Informations de publication
Date de publication:
08 May 2024
08 May 2024
Historique:
received:
07
03
2024
accepted:
17
04
2024
medline:
8
5
2024
pubmed:
8
5
2024
entrez:
8
5
2024
Statut:
epublish
Résumé
Primary Sjögren's Syndrome (pSS) falls within the category of connective tissue diseases, characterized by the presence of autoantibodies such as antinuclear antibodies (ANA). However, according to the classification criteria for pSS, some patients may exhibit a negative result for autoantibodies. Patients with a negative result for autoantibodies may lack typical features of connective tissue diseases, and the immunological state as well as the extent of organ involvement and damage may differ from those with positive autoantibodies. This study aims to compare the clinical phenotypes of patients with positive and negative autoantibodies, providing insights for disease classification and treatment selection for clinicians. Patients with pSS were grouped based on the presence and titers of their autoantibodies. Subsequently, differences in organ damage and laboratory indicators were compared between these groups, aiming to analyze the value of autoantibody titers in assessing the condition of pSS. (1) Patients with positive ANA exhibited elevated levels of inflammatory indicators, including ESR, IgG levels, lip gland biopsy pathology grade, and overall organ involvement, in comparison with patients with negative ANA (P < 0.05). Furthermore, ANA-positivity correlated with a higher occurrence of multi-organ damage, particularly affecting the skin, mucous membranes, and the hematological system (P < 0.05). (2) As ANA titers increased, patients demonstrated elevated levels of IgG and an escalation in organ involvement (P < 0.05). (3) Patients in the positive autoantibody group (positive for antinuclear antibodies, anti-SSA, or anti-SSB antibodies) had higher IgG levels compared to the negative group (P < 0.05). (4) Patients with positive anti-SSA and anti-SSB antibodies exhibited higher levels of inflammatory indicators and IgG compared to other patients (P < 0.05); however, no significant differences were observed in terms of organ involvement and organ damage. Patients with positive ANA in pSS typically exhibit higher levels of inflammation and an increased likelihood of experiencing multi-organ damage. Furthermore, as the ANA titers increase, both inflammation levels and the risk of multi-organ damage also escalate. Additionally, the presence of anti-SSA and anti-SSB antibodies may contribute to an elevated risk of increased inflammation levels, but does not increase the risk of organ damage.
Identifiants
pubmed: 38717644
doi: 10.1007/s10238-024-01357-5
pii: 10.1007/s10238-024-01357-5
doi:
Substances chimiques
Antibodies, Antinuclear
0
Immunoglobulin G
0
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
96Subventions
Organisme : the Fundamental Research Funds for the Central Universities
ID : YD9110002017
Informations de copyright
© 2024. The Author(s).
Références
Both T, Dalm VA, Van Hagen PM, Van Daele PL. Reviewing primary Sjögren’s syndrome: beyond the dryness—from pathophysiology to diagnosis and treatment. Int J Med Sci. 2017;14(3):191–200.
doi: 10.7150/ijms.17718
pubmed: 28367079
pmcid: 5370281
Boothe M, Morris R, Robin N. Stickler syndrome: a review of clinical manifestations and the genetics evaluation. J Pers Med. 2020;10(3):105.
doi: 10.3390/jpm10030105
pubmed: 32867104
pmcid: 7564399
Negrini S, Emmi G, Greco M, Borro M, Sardanelli F, Murdaca G, Indiveri F, Pup-po F. Sjögren’s syndrome: a systemic autoimmune disease. Clin Exp Med. 2022;22(1):9–25.
doi: 10.1007/s10238-021-00728-6
pubmed: 34100160
Fayyaz A, Kurien BT, Scofield RH. Autoantibodies in Sjögren’s Syndrome. Rheum Dis Clin North Am. 2016;42(3):419–34.
doi: 10.1016/j.rdc.2016.03.002
pubmed: 27431345
pmcid: 4955792
André F, Böckle BC. Sjögren’s syndrome. J Dtsch Dermatol Ges. 2022;20(7):980–1002.
pubmed: 35881105
pmcid: 9539881
Jonsson R, Brokstad KA, Jonsson MV, Delaleu N, Skarstein K. Current concepts on Sjögren’s syndrome—classification criteria and biomarkers. Eur J Oral Sci. 2018;126(Suppl):37–48.
doi: 10.1111/eos.12536
pubmed: 30178554
pmcid: 6586012
Quartuccio L, Baldini C, Bartoloni E, Priori R, Carubbi F, Corazza L, Alunno A, Colafrancesco S, Luciano N, Giacomelli R, Gerli R, Valesini G, Bombardieri S, De Vita S. Anti-SSA/SSB-negative Sjögren’s syndrome shows a lower prevalence of lymphoproliferative manifestations, and a lower risk of lymphoma evolution. Autoimmun Rev. 2015;14(11):1019–22.
doi: 10.1016/j.autrev.2015.07.002
pubmed: 26162302
Tarn JR, Howard-Tripp N, Lendrem DW, Mariette X, Saraux A, Devauchelle-Pensec V, Seror R, Skelton AJ, James K, McMeekin P, Al-Ali S, Hackett KL, Lendrem BC, Hargreaves B, Casement J, Mitchell S, Bowman SJ, Price E, Pease CT, Emery P, Lanyon P, Hunter J, Gupta M, Bombardieri M, Sutcliffe N, Pitzalis C, McLaren J, Cooper A, Regan M, Giles I, Isenberg D, Saravanan V, Coady D, Dasgupta B, McHugh N, Young-Min S, Moots R, Gendi N, Akil M, Griffiths B, Johnsen SJA, Norheim KB, Omdal R, Stocken D, Everett C, Fernandez C; Leeds CTRU; Isaacs JD, Gottenberg JE; French ASSESS cohort; Ng WF; UK Primary Sjögren's Syndrome Registry. Symptom-based stratification of patients with primary Sjögren's syndrome: multi-dimensional characterisation of international observational cohorts and reanalyses of randomised clinical trials. Lancet Rheumatol. 2019;1(2): e85–e94.
Mathai SC, Danoff SK. Management of interstitial lung disease associated with connective tissue disease. BMJ. 2016;352: h6819.
doi: 10.1136/bmj.h6819
pubmed: 26912511
pmcid: 6887350
Tešija Kuna A, Đerek L, Drvar V, Kozmar A, Gugo K. Assessment of antinuclear antibodies (ANA): National recommendations on behalf of the Croatian society of medical biochemistry and laboratory medicine. Biochem Med (Zagreb). 2021;31(2): 020502.
doi: 10.11613/BM.2021.020502
pubmed: 33927550
Fisher BA, Jonsson R, Daniels T, Bombardieri M, Brown RM, Morgan P, Bombardieri S, Ng WF, Tzioufas AG, Vitali C, Shirlaw P, Haacke E, Costa S, Bootsma H, Devauchelle-Pensec V, Radstake TR, Mariette X, Richards A, Stack R, Bowman SJ, Barone F; Sjögren's histopathology workshop group (appendix) from ESSENTIAL (EULAR Sjögren's syndrome study group). Standardisation of labial salivary gland histopathology in clinical trials in primary Sjögren's syndrome. Ann Rheum Dis. 2017;76(7):1161–1168.
Zhang W, Li X, Xu D, et al. Diagnosis and treatment of primary Sjogren’s syndrome. Chin Med J. 2020;59(04):269–76.
doi: 10.1097/CM9.0000000000000626
Nocturne G, Mariette X. Advances in understanding the pathogenesis of primary Sjögren’s syndrome. Nat Rev Rheumatol. 2013;9(9):544–56.
doi: 10.1038/nrrheum.2013.110
pubmed: 23857130
Salomonsson S, Jonsson MV, Skarstein K, Brokstad KA, Hjelmström P, Wahren-Herlenius M, Jonsson R. Cellular basis of ectopic germinal center formation and autoantibody production in the target organ of patients with Sjögren’s syndrome. Arthritis Rheum. 2003;48(11):3187–201.
doi: 10.1002/art.11311
pubmed: 14613282
Varin MM, Le Pottier L, Youinou P, Saulep D, Mackay F, Pers JO. B-cell tolerance breakdown in Sjögren’s syndrome: focus on BAFF. Autoimmun Rev. 2010;9(9):604–8.
doi: 10.1016/j.autrev.2010.05.006
pubmed: 20457281
Mariette X, Roux S, Zhang J, Bengoufa D, Lavie F, Zhou T, Kimberly R. The level of BLyS (BAFF) correlates with the titre of autoantibodies in human Sjögren’s syndrome. Ann Rheum Dis. 2003;62(2):168–71.
doi: 10.1136/ard.62.2.168
pubmed: 12525388
pmcid: 1754442
Martín-Nares E, Hernández-Molina G. Novel autoantibodies in Sjögren’s syndrome: A comprehensive review. Autoimmun Rev. 2019;18(2):192–8.
doi: 10.1016/j.autrev.2018.09.003
pubmed: 30572138
Shiboski CH, Shiboski SC, Seror R, et al. International Sjögren's Syndrome Criteria Working Group. 2016 American College of Rheumatology/European League Against Rheumatism classification criteria for primary Sjögren's syndrome: A consensus and data-driven methodology involving three international patient cohorts. Ann Rheum Dis. 2017;76(1):9–16.